MEDIPOST announced the injection of 1·2a phase clinical trial of ‘CARTISTEM^®, which is the cartilage regeneration stem cell medicine, was completed in the clinical trial under progress in U.S.

MEDIPOST implemented last injection of ‘CARTISTEM^®’ to cartilage-defected patients at the 1·2a phase clinical trial on May 28 (Korean time) at Rush University Hospital in Chicago.

MEDIPOST has been implementing the 1·2a phase clinical trial for ‘CARTISTEM^®’ on 12 test subjects in total, at Rush University Hospital in Chicago and Brigham & Women Hospital at Harvard University.

MEDIPOST will track and observe the effectiveness of ‘CARTISTEM^®’ for about one year, and submit the analysis on the assessment result to FDA.